Who
Matthew Gall
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Tango Therapeutics; Chief Financial Officer, Kalaris Therapeutics; Chief Financial Officer, iTeos Therapeutics.
In numbers
- Trades disclosed
- 27
- Buys
- 3
- Sells
- 1
- Bought
- $211K
- Sold
- $232K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 1 Mar 2021
- Last trade
- 1 May 2026
- Last filed
- 5 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 May 2026filed 5 May 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —240,000 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —240,000 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 19 Mar 2026filed 20 Mar 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,000 at $0.00 | filing |
| 19 Mar 2026filed 20 Mar 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,000 at $0.00 | filing |
| 3 Nov 2025filed 3 Nov 2025 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —235,000 at $0.00 | filing |
| 29 Aug 2025filed 29 Aug 2025 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code D | —9,063 | filing |
| 29 Aug 2025filed 29 Aug 2025 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code D | —135,937 | filing |
| 29 Aug 2025filed 29 Aug 2025 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code D | —42,388 | filing |
| 29 Aug 2025filed 29 Aug 2025 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code D | —8,123 | filing |
| 29 Aug 2025filed 29 Aug 2025 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code D | —252,135 | filing |
| 29 Aug 2025filed 29 Aug 2025 | iTeos Therapeutics | SEC FORM 4 Code U | —89,429 | filing |
| 7 Mar 2025filed 11 Mar 2025 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code A | —145,000 at $0.00 | filing |
| 7 Mar 2025filed 11 Mar 2025 | iTeos Therapeutics | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 19 Nov 2024filed 19 Nov 2024 | iTeos Therapeutics | SEC FORM 4 Bought | $39K5,000 at $7.73 | filing |
| 7 Mar 2024filed 8 Mar 2024 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code A | —163,200 at $0.00 | filing |
| 5 Dec 2023filed 7 Dec 2023 | iTeos Therapeutics | SEC FORM 4 Code A | —41,000 at $0.00 | filing |
| 12 Oct 2023filed 12 Oct 2023 | iTeos Therapeutics | SEC FORM 4 Bought | $42K5,000 at $8.37 | filing |
| 9 Mar 2023filed 10 Mar 2023 | iTeos Therapeuticsoption or derivative | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.